The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

N

Neon Hospital

Status

Completed

Conditions

Diabetic Macular Edema

Treatments

Drug: Subconjunctival bevacizumab (Altuzan)

Study type

Interventional

Funder types

Other

Identifiers

NCT02796183
2015-1

Details and patient eligibility

About

This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.

Full description

At baseline, the macular thicknesses of both eyes of the patients with persistant diabetic macular edema were measured by optical coherence tomography. After 3.75mg bevacizumab was injected into subconjunctival space of the eyes with diabetic macular edema. The measurements of the macular thicknesses were repeated by optical coherence tomography in 15th, 30th, 60th day after injections. The macular thickness measurements before and after injection were compared.

Enrollment

20 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Having diffuse diabetic macular edema persisted at least 1 month No intravitreal injection in last 3 months. No retinal laser photocoagulation in last 6 months Not have any other macular disease causing macular edema

Exclusion criteria

Having ischemic macula Intravitreal injection in last 3 months. Retinal laser photocoagulation in last 6 months Have any other macular disease causing macular edema

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Diabetic macular edema
Other group
Description:
Bevacizumab (Altuzan) was injected subconjunctival space of the patients.
Treatment:
Drug: Subconjunctival bevacizumab (Altuzan)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems